3rd Circ. Doubts Par's Exclusive Deal Is Anti-Competitive
The Third Circuit on Tuesday questioned whether an exclusive deal involving a key ingredient in medicine really amounted to anti-competitive conduct, as Fresenius Kabi USA LLC tried to revive its suit...To view the full article, register now.
Already a subscriber? Click here to view full article